Nahoko Kaniwa

National Institute of Infectious Diseases

Papers

Total Citations

H-Index

About

Dr. Nahoko Kaniwa is a distinguished researcher in pharmacogenomics and personalized medicine, with a particular focus on cancer therapeutics. Her work centers on identifying biomarkers that can predict patient responses to chemotherapy, aiming to optimize treatment outcomes and minimize adverse effects. One of her most notable contributions is a 2010 study on survival prediction for pancreatic cancer patients receiving gemcitabine treatment, which has garnered 35 citations. This research employed liquid chromatography-mass spectrometry (LC-MS) to analyze baseline metabolite profiles, seeking biomarkers that could differentiate patients who would benefit from gemcitabine monotherapy from those who would not—a critical need given the drug's variable efficacy in advanced pancreatic cancer. Dr. Kaniwa’s work exemplifies the translation of analytical chemistry into clinical decision-making, helping to pave the way for more tailored oncological care. Her contributions have advanced the understanding of how genetic and metabolic factors influence drug response, making her a key figure in the push toward precision medicine in oncology.